Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 8/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877469 | 0.91 | GRIN2B (0.35) | GRIN2BGRIN1 | |
| SCHEMBL4873965 | 0.90 | GRIN2B (0.41) | GRIN2BMEN1KMT2AKMOGRIN1 | |
| SCHEMBL4876346 | 0.87 | GRIN2B (0.35) | GRIN2B | |
| SCHEMBL4878159 | 0.85 | KCNH2 (0.34) | GRIN2B | |
| SCHEMBL4874257 | 0.84 | GRIN2B (0.34) | GRIN2BGRIN1 | |
| SCHEMBL4873278 | 0.84 | GRIN1 (0.37) | GRIN2BMEN1KMT2AALOX5APKMO | |
| SCHEMBL4874611 | 0.84 | MKNK2 (0.37) | GRIN2BMEN1KMT2A | |
| SCHEMBL4878281 | 0.83 | KCNH2 (0.37) | — | |
| SCHEMBL4876791 | 0.81 | GAA (0.39) | GRIN2BKMT2A | |
| SCHEMBL2997718 | 0.80 | GRIN2B (0.40) | GRIN2BPTGER1GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | GRIN2B 3420/4885MEN1 4834/4885KMT2A 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.